EUVIMEDEUVIMED entdecken
Fallbericht

Presentation and Longer‐Term Outcomes in Mosaic Trisomy 21 Causing Isolated Transient Abnormal Myelopoiesis

Anna-Thérèse Mehra iD, Monica H Wojcik iD

American Journal of Medical Genetics Part A · 2025

DOI: 10.1002/ajmg.a.63979 ↗

Kurz gefasst

Fallbericht in der Zeitschrift American Journal of Medical Genetics Part A, 2025. Verfasst von Anna-Thérèse Mehra und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Newborn Medicine, Department of Pediatrics, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Down Syndrome, GATA1 Transcription Factor, Leukemoid Reaction, Mosaicism. Die Arbeit nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Transient abnormal myelopoiesis (TAM) is a transitory, myeloproliferative condition nearly exclusively present in infants with complete trisomy 21 (T21), or in its rare form, T21 mosaicism. We present here a case study of a neonate diagnosed with T21 mosaicism and TAM who did not exhibit the typical phenotypic features of down syndrome (DS), but displayed hematologic abnormalities, in addition to hepatosplenomegaly. Initial genetic testing suggested acute myeloid leukemia (AML) but subsequent evaluations were indicative of T21 mosaicism confined to the myeloid cell line, with negative results from lymphocytes cultured from a skin biopsy. A pathogenic GATA1 variant was found in the bone marrow in addition to three copies of RUNX1 , associated with aberrant hematopoiesis in TAM. The infant responded to a brief course of chemotherapy and demonstrated normal growth and development at four years of age. In addition to this case, we identified 25 cases from the literature of mosaic T21 restricted to the myeloid cell line supporting normal development following treatment for TAM. As this case and the literature review demonstrate, T21 mosaicism apparently isolated to the bone marrow is unlikely to be associated with systemic or neurodevelopmental manifestations of DS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Down SyndromeGATA1 Transcription FactorLeukemoid ReactionMosaicismMyelopoiesisHumansInfantBone MarrowCore Binding Factor Alpha 2 Subunit

Stichwörter der Autor:innen

down syndromeleukocytosismosaic trisomy 21neonatetransient abnormal myelopoiesis

Substanzen

Core Binding Factor Alpha 2 SubunitGATA1 protein, humanGATA1 Transcription FactorRUNX1 protein, human

Autor:innen und Institutionen

  • Division of Newborn Medicine, Department of Pediatrics, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Genetics and Genomics, Department of Pediatrics, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • The Manton Center for Orphan Disease Research, Department of Pediatrics, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Anna-Thérèse Mehra, Monica H Wojcik

Zitieren

APA

Mehra, A. T., & Wojcik, M. H. (2025). Presentation and Longer‐Term Outcomes in Mosaic Trisomy 21 Causing Isolated Transient Abnormal Myelopoiesis. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.63979

Vancouver

Mehra AT, Wojcik MH. Presentation and Longer‐Term Outcomes in Mosaic Trisomy 21 Causing Isolated Transient Abnormal Myelopoiesis. American Journal of Medical Genetics Part A. 2025. doi:10.1002/ajmg.a.63979

BibTeX
@article{Mehra2025,
  author = {Mehra, Anna-Thérèse and Wojcik, Monica H},
  title = {Presentation and Longer‐Term Outcomes in Mosaic Trisomy 21 Causing Isolated Transient Abnormal Myelopoiesis},
  journal = {American Journal of Medical Genetics Part A},
  year = {2025},
  doi = {10.1002/ajmg.a.63979}
}
Kostenlos starten →